Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook Read more
FDA rejects Disc's rare disease drug despite commissioner's voucher Read more
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments Read more
